Q-omics provides the consensus-scored CHAD profile across patient tissues and cancer cell-line models. CHAD expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CHAD is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, CHAD RNA expression shows 18,430 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, COAD, and DLBC as cancer lineages where CHAD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHAD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHAD survival associations across molecular data types. CHAD RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHAD RNA expression–survival associations across cancer types. High CHAD expression shows unfavorable associations in LGG, but favorable associations in HNSC, BRCA, UVM, LUAD and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CHAD RNA expression.
This table summarizes CHAD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHAD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHAD shows lower tumor expression in COAD, HNSC, KIRP, STAD, THCA and READ. The COAD box plot shows higher CHAD RNA expression in normal versus tumor tissue (log2 FC = −2.722, t-test p < 0.001).
This table shows molecular features associated with CHAD in patient tissues and cancer cell lines. In patient samples, CHAD shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHAD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
